Product Description
Fludrocortisone, a corticosteroid, is used to help control the amount of sodium and fluids in your body. It is used to treat Addison's disease and syndromes where excessive amounts of sodium are lost in the urine. It works by decreasing the amount of sodium that is lost (excreted) in your urine. (Sourced from: https://medlineplus.gov/druginfo/meds/a682549.html)
Mechanisms of Action: MR Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Australia | Austria | Bangladesh | Belgium | Brazil | Bulgaria | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Egypt | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malta | Netherlands | New Zealand | Norway | Peru | Poland | Romania | Russia | Singapore | Slovenia | Spain | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: C.H.U. de RENNES
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Australia
Active Clinical Trial Count: 3
Highest Development Phases
Phase 3: Shock, Septic
Phase 2: Geographic Atrophy|Macular Degeneration
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| HORNbILL | P3 |
Active, not recruiting |
Shock, Septic |
2025-10-27 |
|
| ACTRN12624000997550 | P2 |
Not yet recruiting |
Macular Degeneration|Geographic Atrophy |
None |
|
| ACTRN12624000971538 | P2 |
Not yet recruiting |
Macular Degeneration|Geographic Atrophy |
None |